WHO's 2026 Typhoid Vaccine Position: TCV, Antimicrobial Resistance and the Water-Sanitation-Vaccine

Triangle CA_CATEGORY: Health and Science & Technology CA_GS: GS Paper II, GS Paper III CA_DATE: 31 August 2026 CA_IMAGE: NO WHO's 2026 Typhoid Vaccine Position: TCV, Antimicrobial Resistance and the Water-Sanitation-Vaccine Triangle Why in News?

• WHO issued an updated position paper on typhoid vaccines on 18 August 2026, replacing its 2018 position paper and focusing primarily on Typhoid Conjugate Vaccines.
• The update reflects new evidence on effectiveness, population impact, duration of protection, booster-dose immunogenicity and the spread of antimicrobial-resistant Salmonella Typhi.
• Typhoid is a classic UPSC One Health and public-health topic because vaccination, antimicrobial resistance, drinking-water safety, sanitation and urban governance all interact. Disease Basics
• Typhoid fever is caused by Salmonella enterica serovar Typhi, a human-restricted bacterium transmitted mainly through food or water contaminated with faeces.
• Paratyphoid is caused by related Salmonella Paratyphi serovars and is not prevented by conventional typhoid vaccines directed at the Vi antigen of S. Typhi.
• Symptoms commonly include prolonged fever, headache, abdominal symptoms and weakness; severe disease can cause intestinal bleeding or perforation.
• Because humans are the principal reservoir of S. Typhi, sanitation and safe water can break transmission at population scale. WHO's Preferred Vaccine
• WHO recommends Typhoid Conjugate Vaccine as the preferred vaccine for routine programmatic use because it has improved immunological properties, can be used in younger children and is expected to provide longer protection.
• TCV uses Vi capsular polysaccharide antigen chemically linked to a carrier protein, converting a weak polysaccharide response into a stronger **T-**cell-dependent immune response.
• WHO notes that TCV can be licensed from 6 months of age, depending on product specifications, whereas older unconjugated Vi polysaccharide vaccines are used from 2 years and oral Ty21a from above 6 years.
• The conjugate principle is also used in vaccines against diseases such as Haemophilus influenzae type b and pneumococcal disease. Three WHO-Recommended Typhoid Vaccine Types
• TCV: injectable Vi polysaccharide conjugated to a carrier protein; preferred for routine programmes and suitable for young children.
• Vi-PS: injectable unconjugated Vi polysaccharide vaccine for persons generally 2 years of age and older.
• Ty21a: live attenuated oral vaccine in capsule form, generally for persons older than 6 years.
• Only TCV combines early-age eligibility with the longer-lasting immune characteristics that drive WHO's current preference. Why the 2026 Update Matters
• Evidence accumulated after national introductions in multiple countries now allows WHO to assess population-level impact rather than relying only on pre-licensure trials.
• Duration of protection can vary by age at vaccination and epidemiological setting, so programme design must consider local burden and transmission.
• Booster-dose evidence is becoming more relevant as early TCV cohorts age.
• WHO's shift from the 2018 paper to a 2026 update illustrates how vaccine recommendations evolve with post-introduction evidence. Antimicrobial Resistance
• Drug-resistant S. Typhi reduces the effectiveness of standard antibiotic treatment and can lengthen illness, increase cost and complicate outbreak control.
• Extensively drug-resistant typhoid has demonstrated that pathogens can accumulate resistance to several traditional first-line and later-line antibiotics.
• Vaccination reduces infections and therefore reduces opportunities to prescribe antibiotics, creating an indirect antimicrobial-resistance benefit.
• This is a high-value AMR principle: vaccines are not antibiotics, but they can reduce antibiotic consumption by preventing bacterial disease. Water, Sanitation and Hygiene
• WHO explicitly states that vaccination programmes should be implemented with health education, water-quality improvement, sanitation and better diagnosis and treatment.
• A vaccine can reduce susceptibility, but contaminated municipal water or sewage leakage continues to expose populations.
• Urban typhoid control therefore depends on sewer networks, chlorination, safe food handling, surveillance and rapid repair of water-sewage cross-connections.
• WASH investment provides benefits across diarrhoeal diseases, not only typhoid. Carrier State and Public Health
• Some infected persons can continue to carry and shed S. Typhi after apparent recovery, historically making chronic carriers important in transmission.
• The gallbladder can serve as a site of persistence in some chronic carriers.
• Public-health investigation of outbreaks therefore requires laboratory confirmation and epidemiological tracing rather than symptom-based assumptions.
• Modern surveillance increasingly combines culture, antimicrobial-susceptibility testing and genomic epidemiology. India Linkage
• India has long had endemic typhoid transmission in many settings, and Indian manufacturers have been important in the development and supply of conjugate vaccines.
• WHO safety reviews of Typbar-TCV included data from trials and public/private use, with millions of marketed doses contributing to post-licensure evidence.
• Typhoid burden is heterogeneous across Indian cities and regions, so local surveillance is essential for deciding programme intensity.
• High population density, intermittent piped water and sewage contamination can create conditions favourable for faeco-oral transmission. Surveillance and Diagnostics
• Blood culture remains an important confirmatory method but sensitivity can be affected by prior antibiotics and timing of sample collection.
• Antimicrobial-susceptibility testing guides treatment and detects resistance trends.
• Genomic surveillance can identify circulating lineages, resistance mechanisms and outbreak relationships.
• Reliable incidence data are needed because underdiagnosis can make typhoid appear less common than it actually is. Why TCV Is Different from Polysaccharide Vaccine
• Pure polysaccharide antigens generally produce limited immune memory in young children, while conjugating the polysaccharide to a protein carrier recruits **T-**cell help.
• This improves antibody quality, memory and effectiveness in infancy.
• Conjugate technology is therefore an immunological platform rather than merely a new brand of the same vaccine.
• Prelims questions may test the principle of conjugation, age eligibility or the distinction between live oral and injectable vaccines. Way Forward
• Use local burden, antimicrobial resistance and outbreak data to prioritise TCV introduction or catch-up campaigns.
• Integrate vaccine surveillance with AMR surveillance so reductions in disease and resistant strains can be measured.
• Improve continuous safe-water supply and sewerage because vaccines cannot substitute for WASH.
• Strengthen laboratory capacity and genomic surveillance for S. Typhi and S. Paratyphi.
• Communicate clearly that TCV prevents typhoid caused by S. Typhi, not every febrile or diarrhoeal disease. Prelims Quick Revision
• WHO 2026 typhoid position paper: 18 August 2026; replaces the 2018 paper.
• Preferred vaccine: TCV.
• TCV can be used from 6 months of age depending on product; Vi-PS generally from 2 years; Ty21a oral vaccine above 6 years.
• Pathogen: Salmonella Typhi; transmission: faeco-oral.
• Vaccination + WASH + diagnosis/treatment + AMR surveillance form the complete control strategy. Probable Mains Question Typhoid control demonstrates why vaccines, antimicrobial-resistance policy and urban water-sanitation systems must be designed as one public-health strategy. Discuss.